Alcon Inc.

NYSE:ALC Stock Report

Market Cap: US$32.9b

Alcon Management

Management criteria checks 4/4

Alcon's CEO is David Endicott, appointed in Jul 2018, has a tenure of 7.5 years. total yearly compensation is $11.60M, comprised of 12.3% salary and 87.7% bonuses, including company stock and options. directly owns 0.055% of the company’s shares, worth $18.19M. The average tenure of the management team and the board of directors is 6.6 years and 7.5 years respectively.

Key information

David Endicott

Chief executive officer

US$11.6m

Total compensation

CEO salary percentage12.29%
CEO tenure8yrs
CEO ownership0.06%
Management average tenure6.6yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

Seeking Alpha • May 31

Alcon: Product Cycle Reset Creates An Attractive Entry Point (Initiating Buy)

Summary Alcon receives a buy rating, driven by the launch of Tryptyr in the mature dry eye disease market. Tryptyr's unique mechanism and rapid tear production differentiate it, but commercial adoption hinges on refill rates, payer coverage, and patient persistence. ALC's robust commercial footprint and strong balance sheet support ongoing R&D, M&A, dividends, and buybacks, mitigating financing risks. Key risks include payer restrictions, patient tolerability, competition, and potential growth deceleration post-2026. Read the full article on Seeking Alpha
Seeking Alpha • Feb 04

Alcon: An Eyecare Leader With Strong Profit Margins, But Overheated Valuation

Summary Alcon is downgraded to a hold from my buy rating in fall 2023, after it has gone up +18% since then and now appears overvalued with a 48x earnings multiple. The firm has a strong profit margin vs its sector, low debt/equity vs a key peer Bausch & Lomb, and investment-grade credit ratings. Its positive cashflow growth should help sustain its dividend. Some risks in this sector are product recalls and supply-chain disruptions, as past events have shown us. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04

Alcon Q2: Positive News From Unity VCS/CS And AR-15512

Summary I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $115 per share, driven by new product pipelines and FDA clearances. Alcon's Unity VCS/CS systems received FDA clearance, set for U.S. commercialization in 2025, enhancing their competitive edge in cataract and vitreoretinal surgery markets. Alcon's partnership with Ocumension in China will leverage local distribution and manufacturing to expand their dry eye treatment business, including Systane Ultra and AR-15512. Despite some U.S. market challenges, I project Alcon to achieve 7% organic revenue growth, supported by product innovation and strategic acquisitions. Read the full article on Seeking Alpha
Seeking Alpha • Aug 01

Alcon: Trading At An Undeserved Premium Valuation

Summary Global eye care giant Alcon, Inc. has seen its stock rise some 30% since its late October lows. The company is delivering solid, but hardly spectacular revenue growth, and is seeing much better free cash flow. The stock now trades at a significant valuation premium to the overall market. Is that premium valuation deserved? An analysis of Alcon follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • May 14

Alcon Q1: Robust Product Pipeline Drives Future Growth (Rating Upgrade)

Summary Alcon has experienced robust Q1 growth, driven by double-digit growth in vision care, particularly in the contact lens market. The company's strong revenue growth is attributed to successful product launches, such as TOTAL30 and DAILIES TOTAL1, which have helped Alcon gain market share. Alcon's FY24 forecast shows potential for increased free cash flow, strong revenue growth in vision care, and growth opportunities in the surgical business. Read the full article on Seeking Alpha
Seeking Alpha • Oct 10

Alcon: Buy An Eyecare Leader With $2 Billion In Quarterly Sales

Summary Alcon gets a Buy Rating today, in line with Wall Street consensus. Strengths include earnings growth, share price crossover below 200-day average, outperformance vs. the S&P500 index, and the company's strong cash position. Offsetting factors include a high valuation and poor dividend yield. The downside risk of debt levels was also addressed. Read the full article on Seeking Alpha
Seeking Alpha • Jul 26

Alcon: Lackluster Growth Given Its Valuation

Summary Alcon stock is currently trading at over 30x earnings, which is considered high for a company not expected to deliver EPS above 20 - 25% in the next few years. Despite the high trading multiple, Alcon has a strong business model and is a leader in the eye care industry, with recent positive developments in its product line and services. Alcon's share price is currently inflated due to hopes of significant free cash flow being diverted to shareholders, but I suggest this optimism may be misplaced and recommend a hold rating for the company. Read the full article on Seeking Alpha
Seeking Alpha • Jun 27

Alcon: The Steady Force Of 'Boring'

Summary Alcon is expected to outpace market growth and gain market share in the surgical and vision care sectors, with growth driven by factors such as the increasing global aging population and rise in myopia. Along with Costco, Aon, and Marsh & McLennan, Alcon is another "boring" investment in my portfolio. Alcon's focus on R&D, product innovation, and accelerated free cash flow generation contribute to a positive outlook, earning a "Buy" rating. Read the full article on Seeking Alpha
Seeking Alpha • Feb 13

Alcon reached $199M settlement with J&J Surgical Vision

Eye care company Alcon (NYSE:ALC) has reached a settlement with J&J Surgical Vision on its pending legal proceedings related to femtosecond laser assisted cataract surgery devices. The parties have exchanged cross-licenses of certain intellectual property and other mutually agreed covenants and releases, as part of the settlement. In addition, Alcon (ALC) has agreed to make a one-time payment of $199M to J&J Surgical Vision for those rights and to resolve various worldwide IP disputes relating to this matter.

CEO Compensation Analysis

How has David Endicott's remuneration changed compared to Alcon's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

US$819m

Dec 31 2025US$12mUS$1m

US$980m

Sep 30 2025n/an/a

US$1b

Jun 30 2025n/an/a

US$1b

Mar 31 2025n/an/a

US$1b

Dec 31 2024US$13mUS$1m

US$1b

Sep 30 2024n/an/a

US$1b

Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$1b

Dec 31 2023US$12mUS$1m

US$974m

Sep 30 2023n/an/a

US$450m

Jun 30 2023n/an/a

US$362m

Mar 31 2023n/an/a

US$341m

Dec 31 2022US$10mUS$1m

US$335m

Sep 30 2022n/an/a

US$571m

Jun 30 2022n/an/a

US$457m

Mar 31 2022n/an/a

US$460m

Dec 31 2021US$11mUS$1m

US$376m

Sep 30 2021n/an/a

US$332m

Jun 30 2021n/an/a

US$183m

Mar 31 2021n/an/a

-US$390m

Dec 31 2020US$8mUS$1m

-US$531m

Sep 30 2020n/an/a

-US$717m

Jun 30 2020n/an/a

-US$636m

Mar 31 2020n/an/a

-US$604m

Dec 31 2019US$7mUS$1m

-US$656m

Compensation vs Market: David's total compensation ($USD11.60M) is about average for companies of similar size in the US market ($USD14.54M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Endicott (61 yo)

8yrs
Tenure
US$11,602,744
Compensation

Mr. David J. Endicott serves as Independent Director at MiniMed Group, Inc. since June 29, 2026. He is President and Chief Executive Officer at Aerie Pharmaceuticals, Inc. since November 21, 2022. He had b...

Leadership Team

NamePositionTenureCompensationOwnership
David Endicott
CEO & Director8yrsUS$11.60m0.055%
$ 18.2m
Timothy Stonesifer
Senior VP & CFO7.3yrsno data0.029%
$ 9.5m
Ian Bell
Senior VP & COO1.8yrsno data0.0097%
$ 3.2m
Margaret Buckley
Chief Accounting Officerno datano datano data
Franck Leveiller
SVP of Global Research & Development and Chief Scientific Officer4.1yrsno datano data
Muru Murugappan
Senior VP and Chief Information & Transformation Officerno datano datano data
Daniel Cravens
Vice President of Investor Relationsno datano datano data
Royce Bedward
Senior VPno datano datano data
Kimberly Martin
Senior VP and Chief HR & Corporate Communications6yrsno data0.0073%
$ 2.4m
Leon Sergio Fraustro
Senior VP & President of Americas10.9yrsno data0.0052%
$ 1.7m
Laurent Attias
Senior VP of Corporate Strategyno datano data0.0045%
$ 1.5m
Heather Attra
Senior VP & Chief Quality and Regulatory Affairs Officerno datano datano data
6.6yrs
Average Tenure
58yo
Average Age

Experienced Management: ALC's management team is seasoned and experienced (6.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Endicott
CEO & Director7.5yrsUS$11.60m0.055%
$ 18.2m
F. Ball
Independent Chairman7.5yrsUS$1.39m0.014%
$ 4.7m
Karen May
Independent Director7.5yrsUS$363.41k0.0085%
$ 2.8m
D. Grossman
Independent Vice Chair7.5yrsUS$405.03k0.0045%
$ 1.5m
Thomas Glanzmann
Independent Director7.5yrsUS$381.23k0.0061%
$ 2.0m
Dieter Spälti
Independent Director7.5yrsUS$333.09k0.0072%
$ 2.4m
Richard Herren
independent Directorless than a yearno datano data
Deborah DiSanzo Eldracher
Independent Directorless than a yearUS$113.22k0.000090%
$ 29.6k
Scott Maw
Independent Director7.5yrsUS$367.11k0.0039%
$ 1.3m
Lynn Bleil
Independent Director7.5yrsUS$349.87k0.0026%
$ 838.3k
Ines Poeschel
Independent Director7.5yrsUS$325.16k0.0028%
$ 930.3k
Arthur Cummings
Independent Director7.5yrsUS$313.47k0.0019%
$ 641.0k
7.5yrs
Average Tenure
64.5yo
Average Age

Experienced Board: ALC's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/22 07:18
End of Day Share Price 2026/07/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alcon Inc. is covered by 58 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
null nullBaird
Jeffrey JohnsonBaird